Amneal Pharmaceuticals
AMRX
19.65
-0.65
-3.18%
Amneal Pharmaceuticals
US · AMRX
#1854 by market cap
Listed 1970
19.65
-0.65
-3.18%
Live - 5344 symbols - heartbeat 476s ago
· 2026-10-08 04:01
Pre-market
19.65
0.00%
After-hours
19.65
0.00%
Overnight
19.76
+0.56%
- Market cap
- 6.28B
- P/E (TTM)i
- 40.94
- P/Bi
- 190.78
- EPSi
- 0.22
- Div yieldi
- 0.00%
- 52W posi
- 87%
Reader sentiment
Are you bullish or bearish on AMRX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.31, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +8.05% YoY
Margins
- Gross margin
- 36.88%
- Operating margin
- 13.18%
- Net margin
- 2.39%
Key ratios & quality
- Enterprise valuei
- 8.58B
- Altman Z-Scorei
- 2.31
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.66B | 1.63B | 1.99B | 2.09B | 2.21B | 2.39B | 2.79B | 3.02B |
| Gross profit | 716.40M | 353.00M | 628.39M | 768.97M | 784.71M | 820.57M | 1.02B | 1.11B |
| Selling & admin expenses | 227.85M | 289.60M | 326.73M | 365.50M | 399.70M | 429.68M | 476.44M | 526.83M |
| Research & development | 210.45M | 202.29M | 190.59M | 209.56M | 200.05M | 167.78M | 196.56M | 193.81M |
| Operating profit | 278.11M | -138.89M | 111.08M | 193.91M | 188.92M | 238.75M | 348.37M | 397.91M |
| Pretax profit | -202.72M | -220.24M | -35.78M | 31.37M | -248.13M | -40.27M | -55.01M | 139.21M |
| Tax | -1.42M | 383.33M | -104.36M | 11.20M | 6.66M | 8.45M | 18.86M | 11.28M |
| Net profit | -201.30M | -603.57M | 68.58M | 20.17M | -254.79M | -48.72M | -73.88M | 127.93M |
| Basic EPS | 0 | -3 | 1 | 0 | -1 | 0 | 0 | 0 |
| Diluted EPS | -0.16 | -2.74 | 0.61 | 0.07 | -0.86 | -0.48 | -0.38 | 0.22 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 695.42M | 724.51M | 784.51M | 814.32M | 722.52M | 796.20M |
| Gross profit | 255.89M | 286.25M | 273.97M | 297.19M | 320.11M | 334.51M |
| Selling & admin expenses | 118.29M | 124.27M | 137.82M | 146.46M | 138.86M | 148.72M |
| Research & development | 41.81M | 49.98M | 65.79M | 36.23M | 39.93M | 41.10M |
| Operating profit | 100.92M | 112.01M | 70.49M | 114.50M | 148.27M | 145.98M |
| Pretax profit | 37.49M | 51.71M | -5.22M | 55.24M | 80.18M | 70.99M |
| Tax | 12.87M | 16.10M | -23.36M | 5.66M | 2.18M | 1.38M |
| Net profit | 24.62M | 35.61M | 18.13M | 49.57M | 78.00M | 69.61M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.04 | 0.07 | 0.01 | 0.11 | 0.19 | 0.18 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.29B | 1.21B | 1.55B | 1.52B | 1.41B | 1.38B | 1.59B | 1.91B |
| Cash & ST investments | 213.39M | 151.20M | 341.38M | 247.79M | 25.98M | 91.54M | 110.55M | 282.03M |
| Inventory | 457.22M | 381.07M | 490.65M | 489.39M | 530.74M | 581.38M | 612.45M | 606.30M |
| Total assets | 4.35B | 3.67B | 4.01B | 3.94B | 3.80B | 3.47B | 3.50B | 3.68B |
| Total current liabilities | 553.85M | 550.41M | 676.90M | 677.24M | 752.80M | 846.60M | 1.13B | 881.63M |
| Short-term debt | 21.72M | 36.95M | 57.47M | 46.04M | 104.64M | 227.62M | 340.26M | 21.58M |
| Long-term debt | 2.63B | 2.61B | 2.77B | 2.72B | 2.63B | 2.43B | 2.16B | 2.57B |
| Total liabilities | 3,456,373,000.00 | 3,319,102,000.00 | 3,661,101,000.00 | 3,572,691,000.00 | 3,615,362,000.00 | 3,452,558,000.00 | 3,610,957,000.00 | 3,749,609,000.00 |
| Total equity | 896.36M | 346.79M | 344.93M | 366.97M | 183.98M | 20.01M | -109.51M | -71.33M |
| Retained earnings | -20.92M | -377.88M | -286.82M | -276.20M | -406.18M | -490.18M | -607.06M | -535.01M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.51B | 1.58B | 1.84B | 1.91B | 1.80B | 1.95B |
| Cash & ST investments | 59.19M | 71.54M | 201.25M | 282.03M | 197.66M | 127.64M |
| Inventory | 601.43M | 608.97M | 614.50M | 606.30M | 641.62M | 677.95M |
| Total assets | 3.37B | 3.42B | 3.60B | 3.68B | 3.54B | 3.78B |
| Total current liabilities | 1.08B | 1.11B | 862.11M | 881.63M | 728.05M | 883.19M |
| Short-term debt | 337.54M | 335.41M | 21.47M | 21.58M | 21.49M | 121.42M |
| Long-term debt | 2.15B | 2.15B | 2.57B | 2.57B | 2.57B | 2.56B |
| Total liabilities | 3,424,638,000.00 | 3,535,321,000.00 | 3,709,829,000.00 | 3,749,609,000.00 | 3,586,187,000.00 | 3,743,324,000.00 |
| Total equity | -59.39M | -112.53M | -109.96M | -71.33M | -45.97M | 33.02M |
| Retained earnings | -594.87M | -572.45M | -570.08M | -535.01M | -472.75M | -415.09M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 250.23M | 1.71M | 379.00M | 241.82M | 65.10M | 345.58M | 295.10M | 339.99M |
| Depreciation & amortization | 137.40M | 207.24M | 235.39M | 233.41M | 240.18M | 229.40M | 236.19M | 223.57M |
| Free cash flow | 153.14M | -95.73M | 312.82M | 189.18M | -25.50M | 276.39M | 220.11M | 225.64M |
| Dividends paid | -183.00M | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 218.78M | 152.82M | 347.12M | 256.74M | 35.23M | 99.11M | 118.42M | 312.94M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 7.41M | 83.82M | 118.45M | 130.32M | -26.74M | -21.24M |
| Depreciation & amortization | 60.16M | 60.11M | 54.07M | 49.23M | 43.19M | 47.80M |
| Free cash flow | -10.91M | 56.42M | 95.99M | 84.15M | -48.45M | -143.99M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 68.39M | 83.67M | 238.41M | 312.94M | 204.41M | 139.62M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -35.16 | -98.25 | 34.02 | 3.20 | -39.46 | -52.79 | -- | -- |
| ROA %i | -0.73 | -9.03 | 2.37 | 0.27 | -3.36 | -2.31 | -3.35 | 2.01 |
| ROIC %i | 5.66 | -7.72 | 6.33 | 3.03 | -0.15 | 2.79 | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -27.13 | -30.66 | -- | -- |
| EBIT margin %i | -3.56 | -3.20 | 5.53 | 8.01 | -4.06 | 7.12 | 7.29 | 12.60 |
| FCF / sales %i | 9.21 | -- | 15.70 | 9.04 | -- | 11.55 | 7.88 | 7.47 |
| Current ratioi | 2.32 | 2.20 | 2.29 | 2.24 | 1.88 | 1.63 | 1.41 | 2.17 |
| Quick ratioi | 1.41 | 1.43 | 1.50 | 1.39 | 1.09 | 0.87 | 0.81 | 1.39 |
| Debt / assetsi | 61.83 | 75.56 | 73.51 | 73.00 | 74.89 | 79.21 | 74.06 | 73.11 |
| LT debt / equityi | 528.91 | 1,177.96 | 952.10 | 785.37 | 918.33 | 12,754.15 | -- | -- |
| Interest coveragei | -0.41 | -0.31 | 0.75 | 1.23 | -0.57 | 0.81 | 0.79 | 1.58 |
| Revenue CAGR (3Y) %i | -- | 16.89 | 24.45 | 7.98 | 10.80 | 6.30 | 10.10 | 10.92 |
| Net income CAGR (3Y) %i | -- | -- | -18.41 | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | 37.66 | 7.30 | -- | -4.04 | 5.18 | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -- |
| ROA %i | -0.38 | 0.10 | 0.17 | 2.01 | 3.54 | 4.37 |
| ROIC %i | -- | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 10.88 | 11.87 | 10.74 | 12.60 | 13.77 | 13.75 |
| FCF / sales %i | 8.25 | 9.17 | 8.06 | 7.47 | 6.18 | -- |
| Current ratioi | 1.40 | 1.43 | 2.13 | 2.17 | 2.47 | 2.20 |
| Quick ratioi | 0.80 | 0.83 | 1.31 | 1.39 | 1.51 | 1.37 |
| Debt / assetsi | 76.65 | 75.43 | 74.61 | 73.11 | 76.17 | 73.93 |
| LT debt / equityi | -- | -- | -- | -- | -- | 8,086.06 |
| Interest coveragei | 1.23 | 1.36 | 1.28 | 1.58 | 1.77 | 1.88 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Affordable Medicines is the largest reported line at 61.53% of revenue, across 3 reported segments.
- AvKARE follows at 19.72%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Affordable Medicines61.53%
AvKARE19.72%
Specialty18.75%
Quote time 2026-10-08 04:01:02 · For reference only, not investment advice and not tailored to your situation.